Rebecca Nugent

EBRC Board President

Rebecca is an experienced R&D executive focused on commercializing research in the biotech industry enabling applications such as cell & gene therapies, synthetic biology and genomics. Dr. Nugent has a broad background in engineering biology currently working with emerging companies as a Venture Partner and fractional executive, her past roles led R&D, Operations and product development efforts at life science companies. As the VP of HTP Operations at Tessera Therapeutics she lead manufacturing teams focused on the development of nucleic acid reagents for genetic medicines, At Synthego and Twist Bioscience she developed novel nucleic acid technologies for Genome Engineering, Synthetic Biology and Next-Generation Sequencing Target Enrichment (NGS TE) products. She did her Post-Doc at New England Biolabs and received her Ph.D. in Molecular Biology from the University of Southern California, where she studied yeast genetics with an emphasis on genomic stability.